| (+)-ITD-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| (14S,15R)-14-Deoxyoxacyclododecindione |
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1-Oleoyl lysophosphatidic acid sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
| 264RAD |
|
|
|
|
|
|
|
|
|
|
|
|
|
| 3-Ethyltoluene |
|
|
|
|
|
|
|
|
|
|
|
|
|
| 7-O-Galloyl-D-sedoheptulose |
|
|
|
|
|
|
|
|
|
|
|
|
|
| A 77-01 |
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| A 83-01 |
|
|
|
|
|
|
|
|
|
|
|
|
99.41% |
| A 83-01 (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
98.69% |
| A 83-01 sodium |
|
|
|
|
|
|
|
|
|
|
|
|
98.03% |
| ActRIIB-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ActRIIB-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ActRIIB-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ActRIIB-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ALK-5-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ALK2-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| ALK2-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ALK5-IN-10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ALK5-IN-25 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ALK5-IN-27 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ALK5-IN-28 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ALK5-IN-31 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ALK5-IN-32 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ALK5-IN-33 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ALK5-IN-34 |
|
|
|
|
|
|
|
|
|
|
|
|
98.21% |
| ALK5-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ALK5-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ALK5-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
98.21% |
| ALK5-IN-80 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ALK5-IN-82 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ALK5-IN-85 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| ALK5-IN-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| AMPK activator 12 |
|
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| ANB012 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-ACVR2A Antibody (Ab-14E1) |
|
|
|
|
|
|
|
|
|
|
|
|
97.95% |
| Anti-ACVR2B Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
99.2% |
| Anti-ALK7 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-BMP-4 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-BMP6 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-BMPR1B Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Candida auris β-1, 3 glucans Antibody (2G8) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-INHBB/Activin B Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
95.09% |
| Anti-Mouse/Human/Rat/Monkey/Hamster/Canine/Bovine TGF-β Antibody (1D11.16.8) |
|
|
|
|
|
|
|
|
|
|
|
|
97.44% |
| Autotaxin-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Axl-IN-21 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| AZ12601011 |
|
|
|
|
|
|
|
|
|
|
|
|
99.78% |
| AZ12799734 |
|
|
|
|
|
|
|
|
|
|
|
|
98.67% |
| Bezeotermin alfa |
|
|
|
|
|
|
|
|
|
|
|
|
|
| BI-4659 |
|
|
|
|
|
|
|
|
|
|
|
|
99.78% |
| BIBF0775 |
|
|
|
|
|
|
|
|
|
|
|
|
99.42% |
| Bintrafusp alfa |
|
|
|
|
|
|
|
|
|
|
|
|
97.96% |
| BIO-013077-01 |
|
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| BMP agonist 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| BMP agonist 2 |
|
|
|
|
|
|
|
|
|
|
|
|
99.26% |
| BMP signaling agonist sb4 |
|
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| BMPR2-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| BMPR2-IN-1 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
99.40% |
| BMS-986260 |
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Buloxibutid |
|
|
|
|
|
|
|
|
|
|
|
|
98.94% |
| Buloxibutid hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
| BUR1 |
|
|
|
|
|
|
|
|
|
|
|
|
99.65% |
| Butrin |
|
|
|
|
|
|
|
|
|
|
|
|
|
| CAY10526 |
|
|
|
|
|
|
|
|
|
|
|
|
99.12% |
| CDD-1281 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| CDD-1431 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| CDD-1653 |
|
|
|
|
|
|
|
|
|
|
|
|
99.38% |
| CDD-2789 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Chromenone 1 |
|
|
|
|
|
|
|
|
|
|
|
|
99.78% |
| CJJ300 |
|
|
|
|
|
|
|
|
|
|
|
|
99.36% |
| Clonixin |
|
|
|
|
|
|
|
|
|
|
|
|
98.88% |
| Clonixin-13C,d3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Compound 19A8.8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dalutrafusp alfa |
|
|
|
|
|
|
|
|
|
|
|
|
96.83% |
| Dexamethasone phosphate |
|
|
|
|
|
|
|
|
|
|
|
|
98.89% |
| Dexamethasone phosphate-d4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| DMH-1 |
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| DMH-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dorsomorphin |
|
|
|
|
|
|
|
|
|
|
|
|
99.10% |
| Dorsomorphin dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
99.7% |
| Endotrophin (Mus musculus) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Endotrophin (Mus musculus) TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
| EW-7195 |
|
|
|
|
|
|
|
|
|
|
|
|
98.84% |
| Fidrisertib |
|
|
|
|
|
|
|
|
|
|
|
|
98.58% |
| Galunisertib |
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Galunisertib monohydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
| GDF15 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gdf15 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gdf15 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
| GFH018 |
|
|
|
|
|
|
|
|
|
|
|
|
98.59% |
| GFH018 methylbenzenesulfonate |
|
|
|
|
|
|
|
|
|
|
|
|
|
| GK-136901 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| GLPG3312 |
|
|
|
|
|
|
|
|
|
|
|
|
98.63% |
| GM103 antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
| GSK 3008348 |
|
|
|
|
|
|
|
|
|
|
|
|
98.04% |
| GSK 3008348 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| GW-6604 |
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| GW788388 |
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| H-ILE-ARG-VAL-VAL-MET-OH |
|
|
|
|
|
|
|
|
|
|
|
|
|
| H-Tyr-Ile-Gly-Ser-Arg-NH2 |
|
|
|
|
|
|
|
|
|
|
|
|
98.27% |
| HM-279 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPH-15 |
|
|
|
|
|
|
|
|
|
|
|
|
99% |
| HYL001 |
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| IMM-H007 |
|
|
|
|
|
|
|
|
|
|
|
|
97.69% |
| IN-1130 |
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Itacnosertib |
|
|
|
|
|
|
|
|
|
|
|
|
99.06% |
| Itacnosertib hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
99.43% |
| ITD-1 |
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| J-1063 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| J-1149 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| JMT203 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| K02288 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| K02288 |
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| KBU2046 |
|
|
|
|
|
|
|
|
|
|
|
|
99.52% |
| KER047 |
|
|
|
|
|
|
|
|
|
|
|
|
98.80% |
| KER047 succinate |
|
|
|
|
|
|
|
|
|
|
|
|
98.93% |
| Klotho-derived peptide 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Klotho-derived peptide 1 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| KQFK |
|
|
|
|
|
|
|
|
|
|
|
|
|
| KQFK TFA |
|
|
|
|
|
|
|
|
|
|
|
|
99.55% |
| KRFK |
|
|
|
|
|
|
|
|
|
|
|
|
|
| KRFK TFA |
|
|
|
|
|
|
|
|
|
|
|
|
99.76% |
| KY1070 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| L-744832 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| L-Seryl-L-leucyl-L-leucyl-L-lysine |
|
|
|
|
|
|
|
|
|
|
|
|
|
| LAE-102 |
|
|
|
|
|
|
|
|
|
|
|
|
99.46% |
| LDN-212854 |
|
|
|
|
|
|
|
|
|
|
|
|
99.62% |
| LDN-214117 |
|
|
|
|
|
|
|
|
|
|
|
|
99.54% |
| LDN193189 |
|
|
|
|
|
|
|
|
|
|
|
|
99.72% |
| LDN193189 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| LDN193189 dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
99.50% |
| LDN193189 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
98.62% |
| LDN193189 Tetrahydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| Levistolide A |
|
|
|
|
|
|
|
|
|
|
|
|
99.34% |
| LG190155 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| LIFR/GPBAR1 modulator 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ligusticum cycloprolactam |
|
|
|
|
|
|
|
|
|
|
|
|
|
| LM9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| LSKL, Inhibitor of Thrombospondin (TSP-1) |
|
|
|
|
|
|
|
|
|
|
|
|
99.34% |
| LSKL, Inhibitor of Thrombospondin (TSP-1) TFA |
|
|
|
|
|
|
|
|
|
|
|
|
99.51% |
| LY-364947 |
|
|
|
|
|
|
|
|
|
|
|
|
99.23% |
| LY2109761 |
|
|
|
|
|
|
|
|
|
|
|
|
99.72% |
| LY2382770 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| LY3200882 |
|
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| LY550410 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lysyl-phenylalanyl-lysine |
|
|
|
|
|
|
|
|
|
|
|
|
|
| M4K-2009 |
|
|
|
|
|
|
|
|
|
|
|
|
99.35% |
| M4K2163 dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
98.58% |
| M4K2281 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| M4K2306 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| M4K2308 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maohuoside A |
|
|
|
|
|
|
|
|
|
|
|
|
99.47% |
| MCA17-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Meloside A |
|
|
|
|
|
|
|
|
|
|
|
|
98.72% |
| ML347 |
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| MU1700 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| N-Acetyltaurine hemimagnesium |
|
|
|
|
|
|
|
|
|
|
|
|
|
| N-Acetyltaurine |
|
|
|
|
|
|
|
|
|
|
|
|
98.71% |
| Nadecnemab |
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| Navitoclax dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
| NCX 466 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Neuropathiazol |
|
|
|
|
|
|
|
|
|
|
|
|
98.18% |
| NGM-120 |
|
|
|
|
|
|
|
|
|
|
|
|
99.28% |
| Nicousamide |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Nisevokitug |
|
|
|
|
|
|
|
|
|
|
|
|
97.00% |
| NSC 90469 |
|
|
|
|
|
|
|
|
|
|
|
|
99.41% |
| NUCC-555 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| OD36 |
|
|
|
|
|
|
|
|
|
|
|
|
99.33% |
| OD36 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Omtriptolide sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ontunisertib |
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| p-nitro-Pifithrin-α |
|
|
|
|
|
|
|
|
|
|
|
|
97.0% |
| PD-161570 |
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| Pentabromopseudilin |
|
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| Pentachloropseudilin |
|
|
|
|
|
|
|
|
|
|
|
|
98.88% |
| PF-06952229 |
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| PF-07868489 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Phenamil |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Phosphatidylserine |
|
|
|
|
|
|
|
|
|
|
|
|
98% |
| Pixofisiran |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pixofisiran sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pixofisiran sodium scrambled negative control |
|
|
|
|
|
|
|
|
|
|
|
|
|
| pm26TGF-β1 peptide |
|
|
|
|
|
|
|
|
|
|
|
|
|
| pm26TGF-β1 peptide TFA |
|
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| Ponsegromab |
|
|
|
|
|
|
|
|
|
|
|
|
99.60% |
| PRX-08066 |
|
|
|
|
|
|
|
|
|
|
|
|
97.46% |
| PRX-08066 maleate |
|
|
|
|
|
|
|
|
|
|
|
|
|
| PST3.1a |
|
|
|
|
|
|
|
|
|
|
|
|
|
| R-268712 |
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Ramatercept |
|
|
|
|
|
|
|
|
|
|
|
|
≥99.0% |
| Regiafuran C |
|
|
|
|
|
|
|
|
|
|
|
|
|
| RepSox |
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| RepSox |
|
|
|
|
|
|
|
|
|
|
|
|
|
| RepSox-d5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rilogrotug |
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Rinvatercept |
|
|
|
|
|
|
|
|
|
|
|
|
|
| RKER-216 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| RO-7303509 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rubiadin-1-methyl ether |
|
|
|
|
|
|
|
|
|
|
|
|
98.57% |
| S58 aptamer |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Salviamarinic acid A |
|
|
|
|
|
|
|
|
|
|
|
|
|
| SAR-439459 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| SB 525334 |
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| SB-431542 |
|
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| SB-431542 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| SB-505124 |
|
|
|
|
|
|
|
|
|
|
|
|
99.73% |
| SB-505124 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
98.52% |
| SD-208 |
|
|
|
|
|
|
|
|
|
|
|
|
99.44% |
| SD-208 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| SGC stimulator 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sitaxsentan-13C6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| SJ000291942 |
|
|
|
|
|
|
|
|
|
|
|
|
99.66% |
| SLLK, Control Peptide for TSP1 Inhibitor |
|
|
|
|
|
|
|
|
|
|
|
|
99.70% |
| SLLK, Control Peptide for TSP1 InhibitorTFA |
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| SM 16 |
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| Sotatercept (mIgG2a) |
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| SRI-31277 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| SRI-35241 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| sTGFBR3 antagonist 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Suberic acid |
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| SY-LB-57 |
|
|
|
|
|
|
|
|
|
|
|
|
99.66% |
| TAK-778 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TGF-βRI inhibitor 2 |
|
|
|
|
|
|
|
|
|
|
|
|
98.32% |
| TGF-βRI inhibitor 3 |
|
|
|
|
|
|
|
|
|
|
|
|
99.16% |
| TGFBR1 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tgfbr1 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TGFBR1 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TGFBR1-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TGFβ-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TGFβ-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TGFβ-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
98.03% |
| TGFβ1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
99.47% |
| TGFβ1-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TGFβ1-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TGFβ1-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TGFβR-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TGFβR1 Recombinant Human Active Protein Kinase |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TGFβR2 Recombinant Human Active Protein Kinase |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TGFβRI-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TGFβRI-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
98.21% |
| TGFβRI-IN-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TGFβRI-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TGFβRI-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TGFβRI-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TGFβRII-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TGFβRII-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
99.51% |
| Theophylline-platinum(IV) prodrug-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| THR-123 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| THR-123 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
| THRX-144644 |
|
|
|
|
|
|
|
|
|
|
|
|
99.43% |
| Tiger17 |
|
|
|
|
|
|
|
|
|
|
|
|
98.47% |
| TJN-331 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TP-008 |
|
|
|
|
|
|
|
|
|
|
|
|
99.42% |
| TP-DEA2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TP0427736 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| TP0427736 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| Unasnemab |
|
|
|
|
|
|
|
|
|
|
|
|
99.00% |
| Vactosertib |
|
|
|
|
|
|
|
|
|
|
|
|
99.53% |
| Vactosertib Hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
99.22% |
| Visugromab |
|
|
|
|
|
|
|
|
|
|
|
|
98.40% |
| Visugromab (Powder) |
|
|
|
|
|
|
|
|
|
|
|
|
|
| VPI-2690B |
|
|
|
|
|
|
|
|
|
|
|
|
|
| XST-14 |
|
|
|
|
|
|
|
|
|
|
|
|
99.26% |
| YXX0237 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| YXX0248 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Zilurgisertib |
|
|
|
|
|
|
|
|
|
|
|
|
98.25% |
| Melamine |
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| Garetosmab |
|
|
|
|
|
|
|
|
|
|
|
|
99.57% |
| HCTZ-CH2-HCTZ |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sitaxsentan |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sitaxsentan sodium |
|
|
|
|
|
|
|
|
|
|
|
|
98.83% |
| Stamulumab |
|
|
|
|
|
|
|
|
|
|
|
|
95.07% |
| Tubeimoside II |
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Dexamethasone phosphate disodium |
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Prafnosbart |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Isotoosendanin |
|
|
|
|
|
|
|
|
|
|
|
|
99.51% |
| Isosaponarin |
|
|
|
|
|
|
|
|
|
|
|
|
99.46% |
| Isoastragaloside I |
|
|
|
|
|
|
|
|
|
|
|
|
99.49% |
| Omtriptolide |
|
|
|
|
|
|
|
|
|
|
|
|
97.02% |
| Arecaidine |
|
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| Bimagrumab |
|
|
|
|
|
|
|
|
|
|
|
|
99.31% |
| Zinc chloride, for cell culture |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lysozyme |
|
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| SHR-1701 |
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| Sotatercept |
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Sequoyitol |
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Mogroside III-E |
|
|
|
|
|
|
|
|
|
|
|
|
99.30% |
| Metelimumab |
|
|
|
|
|
|
|
|
|
|
|
|
98.98% |
| Orcinol glucoside |
|
|
|
|
|
|
|
|
|
|
|
|
98.92% |
| Skimmin |
|
|
|
|
|
|
|
|
|
|
|
|
99.64% |
| Curdione |
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| Murlentamab |
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| Lariciresinol |
|
|
|
|
|
|
|
|
|
|
|
|
99.46% |
| Bakkenolide A |
|
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| Cetrimonium bromide |
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |